Zobrazeno 1 - 10
of 20
pro vyhledávání: ''
Autor:
Noboru Yamamoto, Yuichiro Ohe, Hiroshi Nokihara, Yutaka Fujiwara, Takanori Yamamoto, Yasushi Goto, Shintaro Kanda, Tomohide Tamura, Hidehito Horinouchi
Publikováno v:
Cancer Science
Combination antiprogrammed death 1/programmed death‐ligand 1 Ab and platinum‐based chemotherapy is standard first‐line treatment for advanced non‐small‐cell lung cancer without targetable oncogene alterations. We describe the long‐term sa
Autor:
Mitsuhiro Isozaki, Yuka Fujita, Terufumi Kato, Noboru Yamamoto, Toshiaki Takahashi, Naoyuki Nogami, Kazuhiko Nakagawa, Shinsuke Wada, Mizuki Yoshida, Hiroyasu Kaneda, Seiji Niho, Fumito Tsuji, Makoto Nishio, Keith D. Wilner
Publikováno v:
Cancer Science
In a subgroup of Japanese patients in the ARCHER 1050 randomized phase 3 trial, we evaluated the efficacy and safety and determined the effects of dose modifications on adverse events (AE) and therapy management of first‐line oral dacomitinib 45 mg
Persistent restoration to the immunosupportive tumor microenvironment in glioblastoma by bevacizumab
Autor:
Takashi Tamiya, Ryota Tamura, Toshihide Tanaka, Ryuichi Kanai, Yasuharu Akasaki, Yohei Yamamoto, Kazunari Yoshida, Yuichi Murayama, Keisuke Miyake, Kentaro Ohara, Hikaru Sasaki, Yukina Morimoto
Publikováno v:
Cancer Science
Although vascular endothelial growth factor (VEGF) promotes the immunosuppressive microenvironment, the efficacy of bevacizumab (Bev) on tumor immunity has not been fully investigated. The present study used 47 glioblastoma tissues obtained at 3 diff
Autor:
Kensei Tobinai, Masafumi Taniwaki, Yoshihisa Shumiya, Takaaki Chou, Shinsuke Iida, Dai Maruyama
Publikováno v:
Cancer Science
This open‐label multicenter phase 1 study evaluated the safety, tolerability, efficacy, pharmacokinetics and pharmacodynamics of weekly carfilzomib and dexamethasone (Cd) in Japanese patients with relapsed or refractory multiple myeloma (RRMM). Car
Autor:
Yukio Kobayashi, Takahiko Utsumi, Won Seog Kim, Jun Amaki, Ritsuro Suzuki, Yasuo Ejima, Takeshi Maeda, Kazuyuki Shimada, Toshinori Soejima, Bungo Saito, Emiko Shimoda, Yasuhiko Terui, Young Hyeh Ko, Naoyuki Katayama, Seok Jin Kim, Ilseung Choi, Naoko Asano, Kana Miyazaki, Motoko Yamaguchi, Noriko Fukuhara, Masahiko Oguchi, Norifumi Tsukamoto, Nobuko Kubota
Publikováno v:
CANCER SCIENCE. 109(6):2056-2062
Prognosis of patients with localized nasal extranodal natural killer/T-cell lymphoma, nasal type (ENKL) has been improved by non-anthracycline-containing treatments such as concurrent chemoradiotherapy (CCRT). However, some patients experience early
Autor:
Masaharu Murata, Hiroshi Yagi, Kyoko Shirota, Satoshi Fukagawa, Shingo Miyamoto, Chihiro Kiyoshima, Kiyoko Kato, Haruchika Anan, Shin'ichiro Yasunaga, Kohei Miyata, Daisuke Miyahara, Sung Ouk Nam, Takahiro Katsuda, Fusanori Yotsumoto
Publikováno v:
Cancer Science
Ovarian cancer is the most lethal gynecologic malignancy. Recently, several molecularly targeted anticancer agents have been developed for ovarian cancer; however, its prognosis remains extremely poor. The development of molecularly targeted therapy,
Autor:
Kayo Toyosaki, Satoshi Yomoda, Hiroyasu Esumi, Masafumi Ikeda, Nobuo Mochizuki, Hideaki Takahashi, Hiromi Hasegawa, Izumi Ohno, Rumi Fujioka, Shuichi Mitsunaga, Yusuke Hashimoto, Chika Miyoshi, Shogo Nomura, Akihiro Sato, Katsuya Tsuchihara, Ryuji Takahashi, Satoshi Kishino
Publikováno v:
Cancer Science
GBS-01, an extract from the fruit of Arctium lappa L. is an orally administered drug rich in arctigenin, which has been reported to exert antitumor activity by attenuating the tolerance of cancer cells to glucose deprivation. We investigated the maxi
Autor:
Shuichi Mitsunaga, Taiga Otsuka, Rie Sugimoto, Arsene-Bienvenu Loembe, Kei Muro, Masafumi Ikeda, Yusuke Tadayasu, Kohei Inoue, Isao Saito, Takuji Okusaka, Hideki Ueno
Publikováno v:
Cancer Science
This phase I, dose‐escalation study evaluated the safety, preliminary efficacy and pharmacokinetics of nintedanib, a triple angiokinase inhibitor, in Japanese patients with advanced hepatocellular carcinoma and mild/moderate liver impairment. Thirt
Autor:
Tomonari Yamashita, Yasutsuna Sasaki, Shigeto Ueda, Hirofumi Mukai, Toshiaki Saeki, Yoichi Naito, Seiki Takashima, Nobuaki Matsubara, Shoichi Ohwada, Takashi Shigekawa, Fumikata Hara, Kenjiro Aogi
Publikováno v:
Cancer Science
Human epidermal growth factor receptor 3 (HER3) expression in lung and breast cancers has a negative impact on survival. Patritumab, a human anti-HER3 mAb, has shown anticancer activity in preclinical models. This study examined the safety and pharma
Autor:
Nokitaka Setsu, Takeaki Ishii, Tetsuya Nakatsura, Masaaki Kuda, Yukihide Iwamoto, Tomoya Matsunobu, Kunio Iura, Kenichi Kohashi, Akira Maekawa, Yoshinao Oda
Publikováno v:
Cancer Science
Leiomyosarcoma (LMS) of soft tissue is a sarcoma with smooth-muscle differentiation, and conventional chemotherapy does not improve its outcome. The application of novel antitumor agents and precise prognostication has been demanded. The expression o